After a month gap in choosing the new CEO after Michel Vounatsos, Biogen has finally named Christopher Viehbacher as its new CEO.

Clinical trials on 1800 patients with early-stage Alzheimer's has showed that Lecanemab slows the advance of the disease.

There is a new drug, which can probably help in treating Alzheimer's disease, but the authorities are yet to approve it, even though clinic...

Biogen's $56,000 per year treatment price for an average weight person was seen as a significant cost burden on Medicare, which covers more...

The S&P 500 and Dow indexes tracked weekly declines of about 1 per cent, their first since the turn of October, as hot US inflation reading...

The Nasdaq gained the most among the three major indexes, while the bellwether S&P 500 squeaked its way to a second straight record closing...